Education
About Us
Working with TipRanks
Follow Us
Moolec Science (MLEC)
NASDAQ:MLEC
Top Page
Moolec Science
(NASDAQ:MLEC)
Select Model
Select Model
Rating:37Underperform
Price Target:
$3.00
▲(163.16% Upside)
Moolec Science faces significant financial challenges with negative profitability and cash flow issues despite revenue growth. The technical analysis is bearish, and the valuation appears unfavorable with a negative P/E ratio. These factors contribute to a low overall stock score, highlighting the need for improved financial performance and market sentiment.
Moolec Science (MLEC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.42M
Dividend YieldN/A
Average Volume (3M)174.24K
Price to Earnings (P/E)―
Beta (1Y)-0.51
Revenue Growth170.36%
EPS Growth-24.98%
CountryUS
Employees52
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,891,761
10 Day Avg. Volume38,719
30 Day Avg. Volume174,235
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.00Price Target Upside163.16% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering0
Moolec Science Business Overview & Revenue Model
Company DescriptionMoolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and pipeline leverage the agronomic efficiency of used target crops, such as soybeans and peas. It operates in the United States, Europe, and South America. The company was founded in 2008 and is based in Luxembourg.
How the Company Makes MoneyMoolec Science generates revenue through the sale of its plant-based protein ingredients to food manufacturers and other industry players looking to incorporate alternative proteins into their products. The company leverages its proprietary molecular farming technology to produce high-value proteins efficiently and cost-effectively. Key revenue streams include direct sales of protein ingredients and potential licensing agreements for its technology. Strategic partnerships with food industry leaders and agricultural companies also play a significant role in Moolec Science's business model, enhancing its market reach and enabling collaborative product development.
Moolec Science Earnings Call Summary
Earnings Call Date:May 28, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Oct 27, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive sentiment with significant achievements in revenue growth, regulatory approvals, and strategic partnerships. However, there are challenges with increased operating expenses and cash utilization.Q4-2024 Updates
Positive Updates
Significant Revenue Increase
Normalized revenues increased from approximately $1 million in 2023 to $5.8 million in 2024, due to the consolidation of the soy product ingredient business.
Regulatory Approval Breakthrough
Moolec received the first-ever USDA approval for Piggy Sooy, making it the first company in the industry to achieve such a regulatory milestone.
Successful R&D and Commercialization Efforts
Moolec has successfully set up a fully owned plant molecule and biology lab, achieved significant results in transgenic events, and is preparing for the commercialization of Glaso products.
Strategic Partnerships and Growth Plans
Moolec signed an offtake agreement with a major global CPG company for Glaso and an R&D collaboration with Bunge to develop safflower varieties.
Negative Updates
Increased Operating Expenses
SG&A and R&D expenses increased by $3.1 million, mainly due to non-cash items and the consolidation of the soy ingredient business.
Cash Utilization Rise
Cash used in operating activities increased by $1.8 million from $7.5 million in 2023 to $9.3 million in 2024.
Company Guidance
During Moolec Science's fourth quarter and full fiscal year 2024 conference call, the company shared key financial metrics and future guidance. The fiscal year 2024 saw a significant increase in normalized revenues, jumping from approximately $1 million in 2023 to $5.8 million in 2024, largely due to the consolidation of the soy product ingredient business. The cost of sales increased correspondingly, from close to $1 million in 2023 to $4.5 million in 2024, resulting in an annual gross margin that remains undisclosed. Expenses, including SG&A and R&D, rose by $3.1 million, reaching $9.3 million, driven by non-cash items and the soy ingredient business consolidation. Cash utilization in operating activities increased from $7.5 million in 2023 to $9.3 million in 2024, with a significant $4 million reduction in accounts payable. As of Q4 2024, the cash position stood at approximately $5.4 million, bolstered by the strategic purchase of 15,000 tons of HB4 soybean. Looking ahead, Moolec anticipates fiscal year 2025 to be pivotal, with the commercialization of new science-based ingredients like Glaso, supported by a three-year contract with a major CPG company, and efforts to enhance operational efficiencies and regulatory progress.Moolec Science Financial Statement Overview
Summary
Moolec Science exhibits substantial revenue growth but struggles with profitability and cash flow. High operating expenses and negative profit margins indicate ongoing financial challenges, despite promising top-line growth.Income Statement
Moolec Science has shown a vast increase in revenue from zero to over $7.8 million in the TTM period, indicating strong top-line growth. However, the company struggles with profitability, highlighted by negative gross profit margin and net profit margin, primarily due to high operating expenses. Additionally, EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges. Despite revenue growth, the company's margins are concerning, impacting overall income statement performance.30
Negative
Balance Sheet
The balance sheet indicates a high debt-to-equity ratio due to significant liabilities compared to equity, with a current ratio of 7.9 indicating potential solvency issues. Despite this, the company maintains a reasonable equity ratio relative to total assets. However, the negative ROE suggests poor returns on shareholder investments, further highlighting financial instability. The balance sheet reflects Moolec Science's leveraged position, which could pose risks if revenue growth does not translate into profitability.40
Negative
Cash Flow
Moolec Science's cash flow statement shows considerable negative free cash flow, which has worsened over time. The operating cash flow to net income ratio is unfavorable, indicating inefficient cash management from operations. Although the company has raised capital through financing activities, consistent negative free cash flow suggests potential liquidity issues. Overall, the cash flow situation is challenging, and improvements in cash management and operational efficiency are needed.35
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.83M | 5.63M | 905.05K | 0.00 | 0.00 |
| Gross Profit | -639.50K | 472.58K | -143.31K | 0.00 | 0.00 |
| EBITDA | -5.21M | -6.16M | -51.74M | -3.65M | -13.80K |
| Net Income | -8.28M | -7.31M | -51.79M | -4.53M | -13.80K |
Balance Sheet | |||||
| Total Assets | 31.38M | 34.79M | 24.05M | 5.69M | 5.88M |
| Cash, Cash Equivalents and Short-Term Investments | 1.93M | 5.39M | 2.83M | 1.08M | 980.53K |
| Total Debt | 22.09M | 14.68M | 2.65M | 125.00K | 295.00K |
| Total Liabilities | 28.58M | 27.97M | 13.95M | 4.09M | 587.66K |
| Stockholders Equity | 2.80M | 6.82M | 10.11M | 1.60M | 5.29M |
Cash Flow | |||||
| Free Cash Flow | -6.12M | -9.49M | -7.69M | -1.89M | -8.80K |
| Operating Cash Flow | -5.70M | -9.33M | -7.51M | -1.89M | -8.80K |
| Investing Cash Flow | -270.17K | 134.87K | -2.34M | -138.00M | 0.00 |
| Financing Cash Flow | 5.95M | 11.71M | 11.28M | 2.00M | 14.49K |
Moolec Science Technical Analysis
Negative
1.14
Price Trends
2.12
Negative
4.68
Negative
6.08
Negative
Market Momentum
-0.29
Negative
24.92
Positive
26.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLEC, the sentiment is Negative. The current price of 1.14 is below the 20-day moving average (MA) of 1.23, below the 50-day MA of 2.12, and below the 200-day MA of 6.08, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 24.92 is Positive, neither overbought nor oversold. The STOCH value of 26.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLEC.
Moolec Science Risk Analysis
Moolec Science disclosed 3 risk factors in its most recent earnings report. Moolec Science reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Auditors Q2, 2024
2.
Directors and Senior Management Q2, 2024
3.
Advisors Q2, 2024
Moolec Science Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
48 Neutral | $39.93M | -2.79 | -123.35% | ― | 248.62% | 26.22% | |
46 Neutral | $42.73M | -3.75 | ― | ― | ― | 32.31% | |
42 Neutral | $60.22M | -0.49 | -72.83% | ― | -60.16% | ― | |
39 Underperform | $100.14M | -0.85 | ― | ― | ― | 39.60% | |
37 Underperform | $12.42M | ― | -174.68% | ― | 170.36% | -24.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
MLEC
Moolec Science
1.14
-7.65
-87.03%
CLGN
Collplant Holdings
3.14
-1.82
-36.69%
GRCE
Grace Therapeutics
3.09
0.09
3.00%
ALXO
ALX Oncology Holdings
1.87
0.05
2.75%
ALGS
Aligos Therapeutics
9.79
1.13
13.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.